Prop 38's $4.2B Single-Institute Earmark Raises Legal Scrutiny

For corporate and regulatory lawyers, Proposition 38 is a case study in how narrowly drafted initiative language can bypass legislative scrutiny and concentrate public funds in a single private beneficiary. The measure's eligibility criteria—half the $8.4 billion must go to a 'single nonprofit medical research institute'—would, according to a CalMatters investigation cited by the editorial boards, exclude all but the California Institute for Immunology and Immunotherapy, whose co-founder Gary K. Michelson is also the proposition's chief backer. That alignment raises serious questions about conflicts of interest, public trust, and possible legal exposure if voters approve a ballot-box allocation that lacks competitive safeguards.

Two Southern California News Group editorial boards—the San Gabriel Valley Tribune and the Los Angeles Daily News—published coordinated 'No' endorsements against Proposition 38 on August 23, 2026, urging California voters to reject an $8.4 billion bond measure they dismiss as 'a money grab.' The measure is set for the November ballot and would fund immunology and immunotherapy research. The editorial boards do not object to medical research funding as such; their opposition turns on how the borrowed money would be distributed and who stands to benefit.

“

The editorial boards frame Proposition 38 as a form of ballot-box budgeting in which the public is asked to approve a complex $8.4 billion debt obligation without the procedural safeguards of the Legislature.

The fine print drives the controversy. According to the endorsements, half of the $8.4 billion would be awarded as competitive research grants, but the other half must go to 'a single nonprofit medical research institute' that meets very particular requirements. Citing a CalMatters investigation, the editorial boards report that this surgical precision excludes 'all but one institute in the entire state: the California Institute for Immunology and Immunotherapy, whose prominent donor and co-founder is the chief backer of the proposition.' That backer is Gary K. Michelson, a billionaire co-founder of the institute and the chief funder of the Proposition 38 campaign. The boards contend the measure should have been more honest with voters.

This structural design matters because California's initiative process permits interested parties to draft ballot measures, often bypassing the legislative committee hearings, amendments, and fiscal analyses that accompany normal bond proposals. The editorial boards frame Proposition 38 as a form of ballot-box budgeting in which the public is asked to approve a complex $8.4 billion debt obligation without the procedural safeguards of the Legislature. They argue a bond measure issuing only competitive grants, or one that had gone through the public hearing process, would have been preferable. For legal observers, that procedural gap is significant: it concentrates public financial benefit in a named private entity while limiting opportunities for redress, amendment, or independent oversight.

The repayment mechanism sharpens the fiscal debate. Backers told the editorial boards that Proposition 38 will pay for itself because companies that commercialize drugs developed through the research would return 10% of their earnings to help repay the bonds, and that 'the bonds will be repaid with interest, relatively quickly.' The editorial boards respond that if the economics were truly that favorable, the billionaire backers could fund the immunology research privately and attract private investors. This cuts to the central public-finance tension: the state would be borrowing $8.4 billion against a speculative future royalty stream that may never materialize, while taxpayers remain responsible for debt service in the interim.